SecSonar.com

Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Ionis Pharmaceuticals, Inc. (IONS) is a Biotechnology company based in US with a market capitalization of $12.9B. Revenue grew 33.9% year-over-year and free cash flow was negative at -$320M. This page tracks IONS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1.07K employees · IPO May 17, 1991

Valuation

Valuation & price

$74.23 · as of May 17, 2026 · -14.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

26.30

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$85.45$63.07$40.69Jul 25Dec 25Jul 26Jul 7, 25$41.78Jul 9, 25$42.83Jul 11, 25$41.73Jul 15, 25$42.00Jul 17, 25$42.17Jul 21, 25$41.55Jul 23, 25$42.38Jul 25, 25$42.25Jul 29, 25$41.48Jul 31, 25$42.98Aug 4, 25$43.45Aug 6, 25$40.69Aug 11, 25$40.84Aug 13, 25$43.10Aug 15, 25$43.78Aug 19, 25$42.48Aug 21, 25$43.24Aug 25, 25$41.82Aug 27, 25$42.75Aug 29, 25$42.64Sep 3, 25$60.49Sep 5, 25$61.23Sep 9, 25$64.40Sep 11, 25$64.04Sep 16, 25$61.32Sep 18, 25$61.74Sep 22, 25$61.36Sep 24, 25$63.94Sep 26, 25$64.09Sep 30, 25$65.42Oct 2, 25$68.40Oct 6, 25$69.02Oct 8, 25$69.96Oct 10, 25$69.97Oct 14, 25$71.37Oct 16, 25$73.07Oct 21, 25$71.64Oct 23, 25$71.50Oct 27, 25$72.99Oct 29, 25$71.88Oct 31, 25$74.30Nov 4, 25$72.88Nov 6, 25$74.10Nov 10, 25$69.54Nov 12, 25$72.67Nov 14, 25$71.55Nov 18, 25$74.50Nov 20, 25$73.12Nov 25, 25$80.93Nov 28, 25$82.73Dec 2, 25$81.31Dec 4, 25$81.81Dec 8, 25$81.51Dec 10, 25$78.63Dec 12, 25$80.82Dec 16, 25$78.37Dec 18, 25$77.63Dec 22, 25$81.34Dec 24, 25$80.65Dec 29, 25$79.98Jan 2, 26$79.67Jan 6, 26$81.49Jan 8, 26$81.54Jan 12, 26$81.66Jan 14, 26$78.87Jan 16, 26$76.33Jan 21, 26$79.44Jan 23, 26$80.29Jan 27, 26$82.14Jan 29, 26$83.88Feb 2, 26$83.07Feb 4, 26$84.99Feb 9, 26$84.79Feb 11, 26$84.35Feb 13, 26$80.60Feb 18, 26$82.22Feb 20, 26$83.15Feb 24, 26$85.45Feb 26, 26$80.60Mar 2, 26$81.96Mar 4, 26$79.45Mar 6, 26$74.04Mar 10, 26$75.66Mar 12, 26$72.34Mar 17, 26$72.33Mar 19, 26$71.32Mar 23, 26$70.79Mar 25, 26$72.70Mar 27, 26$72.15Mar 31, 26$75.09Apr 2, 26$74.79Apr 7, 26$73.89Apr 9, 26$76.43Apr 13, 26$74.95Apr 15, 26$76.82Apr 17, 26$75.71Apr 22, 26$74.83Apr 24, 26$73.27Apr 28, 26$71.78Apr 30, 26$74.76May 4, 26$75.45May 6, 26$76.85May 8, 26$75.71May 12, 26$75.83May 14, 26$75.68May 18, 26$72.52May 20, 26$75.06May 22, 26$75.56May 28, 26$77.33Jun 1, 26$75.38Jun 3, 26$73.82Jun 5, 26$74.48Jun 9, 26$74.58Jun 11, 26$73.82Jun 15, 26$73.96Jun 17, 26$74.31Jun 22, 26$75.89Jun 24, 26$76.52Jun 26, 26$81.18Jul 2, 26$81.80
$40.6952-week range$86.50
Loading valuation history…

Fundamentals

Key fundamentals

$12.9B

Market cap

33.9%

Revenue growth (YoY)

98.3%

Gross margin

-$320M

Free cash flow (USD)

-$62.7M

Net debt

Net cash position

7.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$372.8MFY 2017$514.2MFY 2018$599.7MFY 2019$1.1BFY 2020$729.3MFY 2021$810.5MFY 2022$587.4MFY 2023$787.6MFY 2024$705.1MFY 2025$944.0M
$372.8M$944M

Free cash flow by year

2016 → 2025

FY 2016$-123.6MFY 2017$136.3MFY 2018$585.2MFY 2019$309.4MFY 2020$-5.2MFY 2021$12.9MFY 2022$-294.5MFY 2023$-335.5MFY 2024$-546.2MFY 2025$-320.0M
-$123.6M-$320M

Gross margin by year

2021 → 2025

FY 202198.7%FY 202297.6%FY 202398.8%FY 202498.4%FY 202598.3%
98.7%98.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

16

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 29, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $2.1M · 10b5-1 PlanSchneider Eugene · EVP, Chf Clinical Develop Ofcr · $2.1MJun 30, 2026Filing
  • Insider sellInsider Sell $246K · 10b5-1 PlanO'NEIL PATRICK R. · EVP CLO & General Counsel · $245.5KJun 30, 2026Filing
  • Insider sellInsider Sell $452K · 10b5-1 PlanBaroldi Joseph · EVP, Chief Business Officer · $451.7KJun 30, 2026Filing
  • Insider sellInsider Sell $839K · 10b5-1 PlanSwayze Eric · EVP Research · $839.5KJun 26, 2026Filing
  • Insider sellInsider Sell $6.8M · 10b5-1 PlanMonia Brett P · Director, Chief Executive Officer · $6.8MJun 26, 2026Filing
  • 8-K eventFDA ApprovalJun 24, 2026Filing
  • Insider sellInsider Sell $588K · 10b5-1 PlanBERTHELSEN SPENCER R · Director · $587.9KJun 16, 2026Filing
  • Insider sellInsider Sell $4.5M · 10b5-1 PlanKordasiewicz Holly B. · EVP, Chief Development Officer · $4.5MJun 16, 2026Filing
  • 8-K eventPositive Study ResultsJun 12, 2026Filing
  • 8-K eventDirector AppointmentJun 8, 2026Filing

Questions

Frequently asked questions

What is Ionis Pharmaceuticals, Inc.'s market cap?

Ionis Pharmaceuticals, Inc. (IONS) has a market capitalization of $12.9B.

What is IONS's P/E ratio?

A meaningful P/E ratio is not available for IONS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is IONS's price-to-book (P/B) ratio?

IONS trades at 26.30 times book value per share.

Are insiders buying IONS stock?

SEC Form 4 filings show no open-market insider buys at Ionis Pharmaceuticals, Inc. in the last 90 days (16 sells).

Same arena

Related companies in Biotechnology

EXEL

Exelixis, Inc.

$12.9B

BBIO

BridgeBio Pharma, Inc.

$13.2B

ASND

Ascendis Pharma A/S

$13.7B

AXSM

Axsome Therapeutics, Inc.

$12B

MDGL

Madrigal Pharmaceuticals, Inc.

$11.5B

JAZZ

Jazz Pharmaceuticals plc

$14.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.